# Progress Note 05 — Focused Visit (Follow-up)

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Howard Hughes (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML006-SYN
- Date: 2026-07-13
- Fictional facility: St. Posthumous Health Center
- Fictional author: Anselm Garrity-Moyo, MD
- Calendar frame: modern shifted

- Visit type: Focused Visit (Follow-up)

## Chief complaint

Ten-week review: sertraline dose, exposure therapy, his staff's part, hearing aids and pain. **S**

## History of present illness

Mr. Hughes returns five weeks after his five-week review. The nurse called two weeks after the dose increase, and sertraline 100 mg has caused only mild sweating at night. His bronchitis from the sick visit cleared within three weeks without antibiotics. He has had nine exposure sessions in all, now twice weekly; he eats food his cook prepares without watching, and he has shaken hands twice at work. His assistant has attended two sessions, and the staff no longer wrap objects in tissue or wash before handing him things; he still asks for sealed milk bottles. Washing and checking take about two hours a day. He has used no opioid other than buprenorphine. Today, with his therapist waiting outside, he used the clinic bathroom and gave a urine sample. His hearing aids were fitted this morning. **S**

| Element | Detail |
|---|---|
| Rituals | About two hours a day; Y-BOCS 19 |
| Sertraline | 100 mg for five weeks; mild night sweats |
| Staff | Tissue-wrapping and the hand-washing rule for staff stopped |
| Buprenorphine | 8 mg twice daily; no other opioid use |
| Hearing aids | Fitted this morning |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Mild night sweats only; weight rising |
| Respiratory | Negative | Cough resolved |
| Musculoskeletal | Positive | Back and chest wall pain milder |
| Psychiatric | Positive | Contamination fears less intense; no thoughts of suicide or of harming anyone |

4 systems reviewed. **S**

## Current medications

- Naloxone 4 mg nasal spray, one spray into one nostril for a suspected opioid overdose, repeated every two to three minutes in the other nostril if needed; two-pack dispensed, with instruction for him and his household staff **S**
- Buprenorphine 8 mg with naloxone 2 mg sublingual film, one film twice daily (16 mg a day), for opioid use disorder and pain; dispensed one week at a time at first **S**
- Acetaminophen 500 mg oral tablet, two tablets three times daily (3,000 mg a day) for pain after the crash, now that codeine combination tablets have stopped **S**
- Sertraline 100 mg oral tablet, two tablets daily (200 mg), the usual target range for OCD **S**

## Allergies

- No known allergy **S**

## Objective

BP 116/74 mmHg; pulse 74 bpm; respirations 14/min; temperature 36.7 °C; oxygen saturation 99% on room air; weight 74.6 kg; BMI 20.4 kg/m². All vital signs are synthetic.

PHQ-9: 5; GAD-7: 8; PEG pain scale: 4.7. All results are synthetic.

## Change since baseline

- PHQ-9: 9 at baseline, 5 at this visit **S**
- GAD-7: 12 at baseline, 8 at this visit **S**
- PEG pain scale: 6.7 at baseline, 4.7 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| General | Well; blood pressure 116/74, pulse 74; weight 74.6 kg, BMI 20.4 |
| Ears | Hearing aids in place; he follows conversation at normal volume |
| Respiratory | Clear |
| Psychiatric | Relaxed; shook hands on leaving; insight good |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Obsessive-compulsive disorder, partial response** (F42.2). Y-BOCS 19, a 32 percent fall after five weeks at 100 mg: a partial response. The APA guideline supports raising the dose toward the top of the range before judging the trial; augmentation is held in reserve until he has had 8 to 12 weeks at the highest dose he tolerates. Safety reviewed: no thoughts of suicide or of harming anyone. **S**
   - Sertraline 200 mg daily.
   - Nurse telephone call in two weeks.
   - Continue exposure and response prevention twice weekly; next steps are restaurant food and meetings without screening visitors.
2. **Opioid use disorder on buprenorphine** (F11.20). Urine test today positive for buprenorphine and negative for fentanyl and other opioids. Stable. **S**
   - Continue buprenorphine; dispensed four weeks at a time.
3. **Bilateral sensorineural hearing loss with hearing aids** (H90.3). Hearing aids fitted today; he can follow speech at normal volume. **S**
   - Audiologist review in one month.
4. **Chronic pain after major trauma** (G89.21). PEG 4.7. **S**
   - Continue physical therapy, now weekly, with a home program.

## Protocol monitoring

Items the monitoring protocol calls for at this visit. **S**

| Domain | Measure | Interval | Status | Detail |
|---|---|---|---|---|
| Survey | OCD severity (Y-BOCS, clinician-rated) and time spent on rituals | Every visit | Completed today | Y-BOCS 19; about two hours a day |
| Referral | Exposure and response prevention: sessions attended and home practice | Weekly, then twice weekly | Completed today | Nine sessions attended, now twice weekly |
| Medication safety | SSRI tolerability and adherence: side effects, sodium, bleeding risk, activation or new suicidal thoughts | Every visit, and two weeks after each start or dose change | Completed today | Nurse call two weeks after the last increase done; mild night sweats only; no activation; dose raised to 200 mg today |
| Self-management | Accommodation by staff, reduced step by step with his consent | Every visit | Completed today | His assistant attended two sessions; staff stopped wrapping objects and washing before handing him things |
| Survey | Depression (PHQ-9) and anxiety (GAD-7) | At baseline and at least monthly during acute treatment | Completed today | PHQ-9 5, item 9 scored 0; GAD-7 8 |
| Survey | Suicide risk review, safety plan and the 988 Suicide & Crisis Lifeline | Every visit | Completed today | No thoughts of suicide or of harming anyone |
| Self-management | Opioid use and cravings (his own account), buprenorphine adherence and side effects (sedation, constipation) | Every visit | Completed today | No cravings and no other opioid use |
| Laboratory | Urine drug test with fentanyl and buprenorphine, with consent | At start, then about monthly in the first months | Completed today | Collected today as a planned exposure: positive for buprenorphine, negative for fentanyl and other opioids |
| Medication safety | Prescription drug monitoring program check | Before every controlled-substance prescription | Completed today | Only this clinic's buprenorphine |
| Medication safety | Naloxone at home and household staff trained | Every visit | Completed today | Naloxone at home |
| Survey | Pain intensity and interference (PEG) and function | Every visit | Completed today | PEG 4.7 |
| Referral | Physical therapy and graded activity | Twice weekly, then weekly | Completed today | Moving to weekly sessions and a home program |
| Examination | Weight, meals and nutrition | Every visit | Completed today | 74.6 kg, up 2.6 kg since intake; three meals a day |
| Laboratory | Kidney function, liver enzymes and albumin | At baseline and at about six months on scheduled acetaminophen | Up to date | Next at about six months |
| Imaging | Hearing: audiometry, hearing aids and use | Audiometry once; hearing aid review after fitting | Completed today | Hearing aids fitted this morning |

## Goal progress

- Y-BOCS down by at least 35 percent (response) within six months. In progress; target 2026-10-05. **S**
- Stop codeine and stay on buprenorphine with no use of other opioids. In progress; target 2026-10-05. **S**
- Pain that lets him work and sleep: PEG at or below 4. In progress; target 2026-10-05. **S**
- Regain weight to at least 76 kg with regular meals. In progress; target 2026-10-05. **S**
- Follow conversation in meetings with hearing aids. In progress; target 2026-10-05. **S**
- Staff stop carrying out rituals for him, step by step, by his own plan. In progress; target 2026-10-05. **S**

## Medication changes

- Stopped: Sertraline 100 mg oral tablet, one tablet daily **S**
- Started: Sertraline 100 mg oral tablet, two tablets daily (200 mg), the usual target range for OCD **S**

## Guideline basis

- Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (2007), American Psychiatric Association (American Journal of Psychiatry 2007;164(7 Suppl):5-53)
- Guideline Watch (March 2013): Practice Guideline for the Treatment of Patients With Obsessive-Compulsive Disorder (Koran LM, Simpson HB), as reported by Psychiatric News (2013), American Psychiatric Association
- Obsessive-compulsive disorder and body dysmorphic disorder: treatment (CG31) (2005), National Institute for Health and Care Excellence
- CDC Clinical Practice Guideline for Prescribing Opioids for Pain - United States, 2022 (2022), Centers for Disease Control and Prevention (MMWR Recommendations and Reports 2022;71(3):1-95)
- The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update (2020), American Society of Addiction Medicine (Journal of Addiction Medicine)
- Prescription Drug Monitoring Programs (PDMPs) (2026), Centers for Disease Control and Prevention
- Hearing loss in adults: assessment and management (NG98) (2018), National Institute for Health and Care Excellence
- VA/DoD Clinical Practice Guideline for Assessment and Management of Patients at Risk for Suicide (2024), United States Department of Veterans Affairs and Department of Defense
- CMID: Clinical Monitoring Intelligence Database, depression, bipolar, and mood disorders monograph (2026), Aether Forge

## Follow-up

- Nurse telephone call in two weeks. Preventive visit in about two months. Twenty-two-week review in about twelve weeks with laboratory tests. Call the clinic or 988 at any time. **S**
- Next scheduled visit 2026-09-14: periodic adult preventive visit. **S**
